When I read things like this, I can't help but be more confident than ever about the potential that is held here. From an article posted today...
Post-Myocardial Infarction Market : Present Scenario and the Growth Prospects 2025
"According to a recent report published by the American Heart Association (AHA) every one in three adults was suffering from some kind of cardiac complication or the other in the U.S. along in 2014. These conditions generally have a high likelihood of leading to myocardial infarction. Furthermore, AHA stated that over 350,000 new cases of heart failure were diagnosed among mail in the U.S. in 2013. Besides this, the Centers for Disease Control and Prevention found in 2009 that over 7 million Americans suffer acute heart attract. Due to this high prevalence of cardiac ailments, the U.S. witnesses over US$108.9 bn incurred on disease cost every year. With little likelihood of this disease burden to decelerate anytime soon, the treatment of post-myocardial infarction will witness increasing demand over the coming years.
Abnormal food habits, stress, and changing lifestyle are also expected to bolster the incidence of heart diseases. All these factors are indicative of the high demand for post-myocardial infarction treatment in developed nations. With the incidence of cardiovascular diseases increasing at emerging nations as well, the post-myocardial infarction market will soon gain pace in developing countries. The market in these nations however might have to face challenge from unfavorable reimbursement policies and low healthcare penetration in remote areas.
The pharmaceutical and biotechnology companies currently exhibiting strong growth in the global post-myocardial infarction market are Merck, GlaxoSmithKline, Novartis, Sanofi, and Pfizer. Besides aiding the market rake higher revenue, these companies are catering to the demand for diverse products in the market. They have been exhibiting increased investment in research and development as well, which is foretold to have a positive influence on the overall market."
Despite all challenges present, seems insane to think that once full data is released and visible to companies like these that Endonovo doesn't come an immediate buyout option for any one of these guys. Imagine waking up one morning to a buyout offer of a few dollar from one of these companies, and seeing our price instantly jump to that range. This is just one of 4 different avenues they are pursuing within their Electroceutical platform. As someone said recently, It does make more sense they could be aiming for something like this to happen, instead of fully bringing their platform to market.
Either way, Im in for the long haul. In the meantime, I will continue to stay in contact with management to ensure any questions of mine are answered, but they have already proven to me they don't care about daily action of their price per share currently, and are seriously looking at this with a longterm mindset. I find it comforting actually to see them not care about timing PR's and releases to increase price per share as with their data release. Why would they care if they know the magnitude of what is on the horizon, especially when Mann can just use it as an opportunity to pick up a few thousand more shares.
Just my opinion. Good luck to all you longs, Im here for the long haul as well. Ignore the noise, know what you own. Im approaching a year of being a shareholder here, and although I could of definitely timed a few of my big block purchases a little better, I think none of that will matter in due time. Cheers to all of you.
